Cabometyx

• 

ESMO 2021: Belzutifan (MK-6482) plus cabozantinib for advanced clear cell RCC

By Sharon Deveson Kell|2021-09-21T08:12:29+00:0021 Sep 2021|Drug treatments|

Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) [...]

Read More

Comments Off on ESMO 2021: Belzutifan (MK-6482) plus cabozantinib for advanced clear cell RCC

• 

ESMO 2021: Cabozantinib for collecting duct carcinoma – the BONSAI study

By Sharon Deveson Kell|2021-09-21T08:06:07+00:0021 Sep 2021|Drug treatments|

Metastatic collecting duct carcinoma is an aggressive form of RCC, [...]

Read More

Comments Off on ESMO 2021: Cabozantinib for collecting duct carcinoma – the BONSAI study

• 

Cabozantinib in pretreated patients with sarcomatoid kidney cancer

By Sharon Deveson Kell|2021-09-07T10:43:10+00:007 Sep 2021|Drug treatments|

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of [...]

Read More

Comments Off on Cabozantinib in pretreated patients with sarcomatoid kidney cancer

• 

ASCO 2021: Baseline characteristics affect survival with nivolumab plus cabozantinib

By Robert|2021-07-07T12:50:28+00:008 Jun 2021|Drug treatments|

Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]

Read More

Comments Off on ASCO 2021: Baseline characteristics affect survival with nivolumab plus cabozantinib

• 

ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer

By Robert|2021-07-07T12:48:55+00:008 Jun 2021|Drug treatments|

The cabozantinib/nivolumab combination has been shown to be effective at [...]

Read More

Comments Off on ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer

• 

ASCO 2021: Telaglenastat plus cabozantinib for metastatic kidney cancer

By Robert|2021-07-07T12:47:34+00:008 Jun 2021|Drug treatments|

Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, [...]

Read More

Comments Off on ASCO 2021: Telaglenastat plus cabozantinib for metastatic kidney cancer

• 

ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer

By Robert|2021-07-07T12:44:15+00:007 Jun 2021|Drug treatments|

The cabozantinib/nivolumab combination has been shown to be effective at [...]

Read More

Comments Off on ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer

• 

Nivolumab/cabozantinib combination approved in EU for first-line kidney cancer treatment

By Robert|2021-07-07T10:47:26+00:006 Apr 2021|Drug treatments|

The European Commission has approved the use of the nivolumab [...]

Read More

Comments Off on Nivolumab/cabozantinib combination approved in EU for first-line kidney cancer treatment

• 

Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer

By Sophie|2021-03-09T14:30:03+00:001 Mar 2021|Uncategorized|

The Committee for Medicinal Products for Human Use (CHMP) of [...]

Read More

Comments Off on Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer

• 

ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

By Sharon Kell|2021-02-15T10:03:32+00:0015 Feb 2021|Drug treatments|

A gene called MET codes for a protein called MET [...]

Read More

Comments Off on ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer